|
Robert H. Lurie Comprehensive Cancer Center: Posted on Monday, February 04, 2013 7:51 PM
 Peggy Gilbertsen, RN, is the Lurie Cancer Center's Clinical Trials Recruitment Coordinator, a newly-created position within the Clinical Research Office (CRO). An experienced oncology research nurse with a long history at the Lurie Cancer Center, Peggy is developing a clinical trials education program for patients, caregivers and community members.
What are clinical trials? In cancer care, clinical trials are studies that are designed to answer questions about new ways to prevent, diagnose and treat cancer. |
|
|
Posted on Friday, December 07, 2012 10:31 PM
Celgene Corporation (Celgene) conducted a phase III clinical trial with the intent to show that the combination of its chemotherapy drug, ABRAXANE®, with gemcitabine would improve overall survival in patients with untreated, metastatic pancreatic adenocarcinoma when compared with gemcitabine alone. Use of gemcitabine alone has been the standard of care for pancreatic cancer.
In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to gemcitabine alone. |
|
|
NCI: Posted on Thursday, May 31, 2012 4:32 PM
In a phase III clinical trial, the antipsychotic drug olanzapine (Zyprexa) was significantly more effective than metoclopramide (Reglan) in controlling chemotherapy-induced nausea and vomiting (CINV) that occurs in some patients despite preventive treatment for these side effects. (Olanzapine is approved by the Food and Drug Administration to treat schizophrenia and bipolar disorder.) Dr. Rudolph Navari of Indiana University School of Medicine-South Bend presented the results at a May 16 press briefing held in advance of the American Society of Clinical Oncology (ASCO) annual meeting . |
|
|
NCI: Posted on Thursday, May 31, 2012 4:03 PM
Preliminary results from a phase I clinical trial suggest that the targeted drug crizotinib (Xalkori) may be effective in children with cancer whose tumors harbor genetic alterations in the ALK gene. In some children, the drug caused all signs of the disease to disappear (complete response). Crizotinib is already approved by the Food and Drug Administration to treat patients with lung cancer whose tumors have ALK mutations. The findings were presented at a press briefing on May 16 in advance of the American Society of Clinical Oncology (ASCO) annual meeting . |
|
|
Nwaokai-Beecham: Posted on Thursday, November 03, 2011 12:06 AM
 The Northwestern Brain Tumor InstituteRobert H. Lurie Comprehensive Cancer Center of Northwestern University is offering the presentation of Jeffery Raizer, MD to speak on the topic of "How Does A Brain Tumor Affect Me Tuesday, November 29th ,2011 6:30 to 7:30 pm This presentation is offered free of charge at Gilda's Club of Chicago, a free cancer support community. RSVP at (312) 464-9900 or www.gildasclubchicago.org. Event address is 537 N. Wells St., Chicago, Illinois at Gilda's Club. |
|
|
Nwaokai-Beecham: Posted on Sunday, October 09, 2011 5:58 PM
Below are 3 events pertinent to cancer care. If you are interested, click on the link to the Events page with more information.
1. Thoracic Oncology Public Education Forum and Reception CLICK HERE FOR ALL 3 EVENTS.
2. AWARE for ALL event that explains about clinical trials for cancer and discusses if you could be a candidate.
3. Brain Tumor Patient & Caregiver Forum
For more information on cancer buy "Memoirs of Cancer" book, HERE Now at a temporary sale price of $12.95. |
|
|
NCI/ Nwaokai-Beecham: Posted on Thursday, September 22, 2011 4:42 PM
Phase III clinical trials are the "gold standard" in oncology research, providing the highest level of evidence to support the effectiveness of cancer treatments. These trials usually involve hundreds of patients at multiple sites, cost millions of dollars, and take years to complete. Most important, the published results of a phase III trial can substantially change the standard of care for a particular tumor type or stage of disease. The American Society of Clinical Oncology (ASCO) annual meeting, the largest meeting of its kind for oncologists, often provides a "first look" at potentially practice-changing clinical trial results, which are subsequently fleshed out in reports published in peer-reviewed journals. |
|
|
NCI: Posted on Wednesday, September 21, 2011 5:02 PM
Name of the TrialNatural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) (NCI-10-C-0096). See the protocol summary.
Principal Investigator
Dr. Ola Landgren, NCI Center for Cancer Research
Why This Trial Is ImportantMultiple myeloma is a rare type of cancer in which abnormal plasma, or myeloma, cells collect in the bone marrow and other soft tissue. These abnormal cells can form tumors that damage bone directly. They also produce large amounts of antibodies, known as |
|
|
Posted on Monday, August 15, 2011 8:32 PM
See if the PICASSO 3 Trial is Right for You.
The PICASSO 3 Trial is a clinical investigation of Palifosfamide for the treatment of soft-tissue sarcoma. If you have been diagnosed with advanced soft-tissue sarcoma and are 18 years or older, you may be eligible to participate in this trial. For more go to: |
|
